Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838325 | 0.72 | EPHX2 (0.33) | ALDH1A1MAPT | |
| SCHEMBL7485036 | 0.70 | NOTUM (0.35) | NOTUM | |
| SCHEMBL7038707 | 0.70 | NOTUM (0.35) | NOTUM | |
| SCHEMBL7019329 | 0.67 | MAPT (0.35) | ALDH1A1LMNAMAPTHTTHSD17B10 | |
| SCHEMBL17635541 | 0.64 | — | — | |
| SCHEMBL21899214 | 0.64 | PIK3CA (0.35) | — | |
| SCHEMBL15331086 | 0.62 | EPHX2 (0.30) | — | |
| SCHEMBL23558509 | 0.62 | — | — | |
| SCHEMBL20283648 | 0.62 | — | — | |
| SCHEMBL22623129 | 0.62 | PKM (0.42) | ALDH1A1MAPTPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20190350940-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2019-11-21 | — | — | US | disclosed |
| US-10342801-B2 | Platinum compounds, compositions, and uses thereof | PLACON THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10322137-B2 | Platinum compounds, compositions, and uses thereof | PLACON THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180221508-A1 | COMPOSITIONS AND METHODS FOR IMMUNOMODULATION | TVA (ABC), LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180221503-A1 | COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES | TVA (ABC), LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180186823-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186823-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9937187-B2 | Platinum compounds, compositions, and uses thereof | PLACON THERAPEUTICS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180008614-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20160317549-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9403858-B2 | Platinum compounds, compositions, and uses thereof | PLACON THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160068557-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068557-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | BID, PDCD1LG2, CD274 | IDH1 254/4885ALDH1A1 4272/4885LMNA 3727/4885 |
| US-20180221503-A1 | COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES | CD47, FCGR3B, FCGR1A | IDH1 786/4885ALDH1A1 1932/4885LMNA 4477/4885 |
| US-10342801-B2 | Platinum compounds, compositions, and uses thereof | TP53, MSH2, FANCI | IDH1 7/4885ALDH1A1 3219/4885LMNA 3047/4885 |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | IDH1 2127/4885ALDH1A1 1330/4885LMNA 1652/4885 |
| US-10322137-B2 | Platinum compounds, compositions, and uses thereof | BID, PDCD1LG2, CD274 | IDH1 254/4885ALDH1A1 4272/4885LMNA 3727/4885 |
| US-20180221508-A1 | COMPOSITIONS AND METHODS FOR IMMUNOMODULATION | CD47, ICOS, PBK | IDH1 2028/4885ALDH1A1 3727/4885LMNA 4298/4885 |
| US-20180008614-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | BID, PDCD1LG2, CD274 | IDH1 254/4885ALDH1A1 4272/4885LMNA 3727/4885 |
| US-20180186823-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | PDCD1LG2, CXCR3, CD274 | IDH1 413/4885ALDH1A1 4486/4885LMNA 4166/4885 |
| US-20160317549-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | BID, PDCD1LG2, CD274 | IDH1 254/4885ALDH1A1 4272/4885LMNA 3727/4885 |
| US-20190350940-A1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | TP53, MSH2, FANCI | IDH1 7/4885ALDH1A1 3219/4885LMNA 3047/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | IDH1 2933/4885ALDH1A1 2528/4885LMNA 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.